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Abstract
Osteoarthritis is a form of chronic joint inflammation caused by the deterioration of 
the joint cartilage, accompanied by chronic pain, lameness and stiffness, particularly 
after prolonged activity. Alternative treatments of canine osteoarthritis would be 
desirable and, recently nutraceuticals, have been proposed for this purpose. Twenty 
cross breed adult dogs affected by osteoarthritis were enrolled and equally divided 
into two groups (control vs. experimental). The nutritional supplement (Dynamopet 
srl, Verone, Italy) was administered for 90 days to the dogs of the experimental group 
in order to evaluate its metabolic and locomotor effects. All the clinical signs (lame-
ness, pain on manipulation and palpation, range of motion and joint swelling) signifi-
cantly (p < 0.01) improved during the trial as regards the experimental group. This 
group showed a significantly lower joint score than the control group (mean value 
7.40 vs. 3.80). With regard to haematology, the mean corpuscular volume resulted 
significantly (p < 0.01) higher in the experimental group, i.e. alkaline phosphatase, 
cholesterol and triglycerides values decreased and were significantly (p < 0.01) lower 
than the control one, thus suggesting an improvement in bone remodelling and lipid 
metabolism. A decrease in the reactive oxygen metabolites and an increase in the 
biological antioxidant potential demonstrated an improvement in oxidative stress 
during the trial in the experimental group compare to the control group. Interleukins 
6 decreased in the experimental group, while interleukins 10 resulted in the opposite 
trend. Moreover, the administration of up to 3 months of the studied supplement was 
well tolerated in the dogs and caused no adverse effects.
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1  | INTRODUC TION
Osteoarthritis (OA) is a form of chronic joint inflammation caused 
by the deterioration of the joint cartilage. It is highly prevalent in 
dogs (Aragon, Hofmeister, & Budsberg, 2007; Paster et al., 2005; 
Smith et al., 2006), mainly in overweight and large breed dogs. Some 
breeds (i.e. the Labrador Retriever, the German Shephard etc.) are 
even genetically predisposed to develop arthritis (Anderson et al., 
2018). There is no known cause for primary OA, while there are a 
wide variety of causes for secondary OA, such as traumas, abnormal 
wear on the joints and cartilages, the hip or elbow dysplasia, the dis-
location of the kneecap or shoulder, and dissecans osteochondritis. 
Finally, obese dogs, because of the high stress levels on their joints, 
and dogs with disorders such as diabetes, prolonged steroid treat-
ment, and hyper laxity may also be at a higher risk of OA (Sanderson, 
2012). The disease is accompanied by chronic pain, lameness and 
stiffness, particularly after prolonged activity.Their quality of life is 
reduced, leading finally to the loss of joint functions and mobility. 
Currently no cure exists and the pharmacological treatment is limited 
to clinical signs alleviation. For this reason, the therapeutic manage-
ment of OA in dogs is dominated by non- steroidal anti- inflammatory 
drugs (NSAIDs), which are only able to treat the symptoms of OA by 
decreasing the pain and inflammation (Curry, Cogar, & Cook, 2005; 
Innes, Fuller, Grover, Kelly, & Burn, 2003). Unfortunately, the use 
of NSAIDs may be associated with detrimental effects, especially 
gastrointestinal adverse effects (Buttgereit, Burmester, & Simon, 
2001). Besides pain relief, preventing the cartilage degradation is 
an important objective for the treatment and requires the long- term 
use of safe modalities. Indeed, the absence of any cure reinforces 
the importance of prevention (Innes et al., 2003). For these reasons, 
alternative treatments of canine osteoarthritis would be desirable 
and, recently, nutraceuticals have been proposed for this purpose 
(Colitti, Gaspardo, Della Pria, Scaini, & Stefanon, 2012; Henrotin, 
Kurz, & Aigner, 2005; Innes et al., 2003). In addition, some herbal 
medicinal products (nutraceuticals of plant origin) have been shown 
to interact with the mediators of the inflammation and, therefore, 
may be used in the treatment of OA (Cameron et al., 2009). These 
products can also act as free radical involving use through other 
mechanisms. However up to now, few clinical trials have been car-
ried out to substantiate the safety and efficacy of herbal medicines, 
which are also not free of potentially serious adverse effects.
Glucosamine and chondroitine sulphate are popular supple-
ments used to treat the pain and loss of functions associated with 
osteoarthritis. Several studies on dogs showed significant improve-
ment in pain scores with the administration per os of both sub-
stances (D'Altilio et al., 2007; Gupta et al., 2012; Steagall et al., 2007; 
Vassalotti et al., 2017).
Ribes nigrum is a perennial shrub which is native of central Europe 
and northern Asia. The phenolic and anthocyanin compounds, in as-
sociation with the high levels of vitamin C, confer on the blackcur-
rant fruit specific antioxidant capacities (Moyer, Hummer, Finn, Frei, 
& Wrolstad, 2002). Regarding the anti- microbial effects, anthocya-
nins have been demonstrated to possess antimicrobial capabilities 
against a variety of bacteria, in particular Gram+ (Puupponen- Pimia 
et al., 2001).
The Krill oil, extracted from the Antarctic krill (Euphausia su-
perba), is known for its anti- oxidative effect, due to astaxanthin, 
which keeps the ω- 3 polyunsaturated fatty acids (PUFA) intact and 
thereby preserves them from oxidation (Tou, Jaczynski, & Chen, 
2007; Winther, Hoem, Berge, & Reubsaet, 2011). An increasing 
number of studies on animals as well as on humans demonstrate 
the health benefits of PUFA, in particular EPA (C20:5 ω- 3) and DHA 
(C22:6 ω- 3) (Dawczynski, Jentsch, Schweitzer, Hammer, & Strobel, 
2013; Nestel et al., 2015). Cardiovascular benefits have been re-
ported, providing an anti- inflammatory effect (Sudheendran, Chang, 
& Deckelbaum, 2010).
Shiitake (Lentinus edodes) possess interesting nutritional charac-
teristics and medicinal properties used by oriental cultures. Shiitake 
mushroom is known for several therapeutic actions such as anti-
oxidant and antimicrobial properties, because of the diversity of 
its components (such as phenolic acids and tocopherols) which are 
able to trap reactive oxygen/nitrogen species and inflammatory 
mediators (Zembron- Lacny, Gajewski, Naczk, & Siatkowski, 2013). 
In addition, Lentinula edodes- derived nondigestible carbohydrates 
have been shown to possess health benefits on gut microbiota (Xu 
& Zhang, 2015).
Equisetum arvense, native to the Arctic and temperate regions of 
Europe, belongs to the Equisetopsida family, and it is commonly used as 
a herbal remedy. The phytotherapic properties are anti- bacterial (Bessa 
Pereira	et	al.,	2012;	Milovanović,	Radulović,	Todorović,	Stanković,	&	
Stojanović,	2007),	antioxidant	(Cetojević-	Simin	et	al.,	2010;	Wu	et	al.,	
2010) and anti- inflammatory (Gründemann et al., 2014).
Equisetum arvense is especially known for its mineralizing activ-
ity. In the bone tissue the silicon enables the deposit of calcium in 
the active sites of bone calcification, especially in the early stages of 
growth (Jugdaohsingh, 2007).
Boswellia serrata is a branching tree native to the hilly regions of 
India. It produces an aromatic resin that is used for medicinal pur-
poses. Comblain, Serisier, Barthelemy, Balligand, and Henrotin (2015) 
showed that Boswellia resin administered for 6 weeks in dogs helped 
to reduce lameness (when moving or after a long rest), local pain and 
stiff gait (Reichling, Schmokel, Fitzi, Bucher, & Saller, 2004). The anti- 
inflammatory effects of Boswellia and boswellic acids have been linked 
to the ability to inhibit the synthesis of leukotrienes, the chemical me-
diators of the inflammatory process in various inflammatory diseases, 
including arthritis (Kimmatkar, Thawani, Hingorani, & Khiyani, 2003).
Both Boswellia serrata and Equisetum arvense are mentioned in 
phytovigilance as possible modulators of cytochrome P450 action 
but the modulating action of these two medicinal plants seems 
strongly dose- related. In 2006, Frank and Unger described Boswellia 
serrata as an inhibitor of numerous cytochrome P450 enzymes, while 
more recently, Dey, Chaskar, Athavale, and Chitre (2015) when using 
Boswellia serrata in association with other medicinal plants, did not 
find such inhibitory activity and hypothesized that a particularly high 
dose of Boswellia extract is required to act on cytochrome P450 
enzymes.
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A similar cytochrome inhibitory action was also described as re-
gards Equisetum arvense (van den Bout- van den Beukel, Koopmans, 
van der Ven, De Smet, & Burger, 2006), reporting on how the action 
of antiretroviral drugs is reduced by the simultaneous intake of the 
preparation based on some medicinal plants, including Equisetum 
arvense.
Curcuma longa is an aromatic substance of vegetable origin 
(spice) with numerous biological activities, anti- inflammatory, anti-
oxidant as well as cardiovascular benefits (Chattopadhyay, Biswas, 
Bandyopadhyay, & Banerjee, 2004; Teiten, Eifes, Dicato, & Diederich, 
2010). These effects are due to diarylheptanoid compounds known 
as curcuminoids, which are considered the main active principles of 
the plant, although their bioavailability was shown to be poor be-
cause of scarce absorption, rapid metabolism and systemic elimina-
tion (Ireson et al., 2001). Curcuma longa has been widely studied for 
its modulating capacity of cytochrome P450 action. In particular, it 
has been shown that the plant possesses the ability to inhibit the ac-
tivity of CYP2A1 and CYP2B1 (Walle & Walle, 2007). Nandal, Dhir, 
Kuhad, Sharma, and Chopra (2009) reported an anti- inflammatory 
activity with regard to Curcuma longa, and a possible synergy with 
the most common non- steroidal anti- inflammatory drugs, and so en-
hancing their anti- inflammatory action without increasing the inci-
dence of harmful side effects.
Harpagophytum procumbens, also called Devil's claw, contains in 
its roots two main bioactive components, harpagoside and harp-
agide, implicated in its anti- inflammatory effects. It is a herbal sub-
stance commonly found in southern African countries, where its 
tubers have been used by native people to treat rheumatism, ar-
thritis, inflammation, and stomach disorders (Fiebich, Muñoz, Rose, 
Weiss, & Mc Gregor, 2012; Inaba, Murata, Naruto, & Matsuda, 
2010; Sanders & Grundmann, 2001). The anti- inflammatory activity 
of harpagide may alleviate bone- associated diseases, in the symp-
tomatic treatment of osteoarthritis (Brien, Lewith, & McGregor, 
2006), arthritis and other rheumatic diseases (Setty & Sigal, 2005). 
Various studies excluded interaction between Harpagophytum pro-
cumbens root and cytochrome P450 (Modarai, Suter, Kortenkamp, & 
Heinrich, 2011). On the other hand, an in vitro test demonstrates its 
inhibitory activity in the expression of cyclooxygenase 2 (COX- 2), 
an enzyme involved in the inflammatory processes of osteoarthritis 
(Abdelouahab & Heard, 2008). Another in vitro studied evaluated 
the effect of the Harpagophytum procumbens on the inflammation 
induced by lipopolysaccharide on fibroblasts in mice, showing that 
its aqueous extract inhibits the synthesis of prostaglandin E2 and 
nitric oxide by inhibiting the increase in COX2 and the expression of 
mRNA specific for the inducible Nitric Oxide Synthase (iNOS) gene 
(Jang et al., 2003). By contrary, other authors reported that the ad-
ministration of Harpagophytum procumbens did not affect plasma 
concentrations of prostaglandins and other eicosanoids, therefore 
hypothesizing a mechanism different from that of the common 
NSAIDs (Moussard, Alber, Toubin, Thevenon, & Henry, 1992). For 
this reason the clinical use of Harpagophytum procumbens is not 
complicated by the gastrointestinal side effects typical of NSAIDs 
and can be favorably associated with their use; even if it has been 
recommended that use should be not prolonged and/or interrupted 
by periods of suspension (Firenzuoli, 2001).
These results indicate that Harpagophytum procumbens pos-
sesses an anti- inflammatory action which is expressed through the 
suppression of COX2 and the expression of iNOS.
Oxidative stress is implicated in the pathogenesis of many dis-
eases and inflammatory conditions. Reactive oxygen species (ROS) 
are products of a normal cellular metabolism and are formed during 
the enzymatic reactions of intercellular and intracellular signalling. 
Physiological and/or pathological mechanisms can cause an over- 
production of ROS and, consequently, oxidative stress, i.e. a state in 
which an oxidant- generating system overcomes an antioxidant de-
fence system. The process of oxidative phosphorylation might be af-
fected because of a possible damage to proteins and membrane lipids 
(Panda, Patra, Nandi, & Swarup, 2009). It is known that the association 
of different compounds in phytotherapy often exerts a synergic activ-
ity. If this is so, the association of these components should guarantee 
a beneficial effect by acting on the different pathways of the oxidative 
stress and inflammatory response (Mastellone et al., 2016).
Although some information is available in the literature regarding 
the substances included in the formula, no study has tested the ef-
fectiveness of their combination. Indeed, no information concerning 
metabolic effects, tolerance and benefits is presently available for 
this nutritional supplement. Further, the use of nutraceuticals as well 
as phytotherapics in veterinary medicine is not often supported by 
an exhaustive scientific literature.
The aim of the present study was to verify the effects of the 
administration of Dìnamic™ (Dynamopet srl, Verone, Italy) in dogs 
affected by OA.
2  | METHODS
2.1 | Ethic statement
This study has been reviewed by the Ethical Animal Care and Use 
Committee of the University on Napoli Federico II and received for-
mal Institutional approval (prot. N 71185/2015 on the 21st of July 
2015) in accordance with local and national law, regulations and 
guidelines. This study avoided any discomfort for the animals by 
using proper clinical management. The blood collection was carried 
out after infurming the owner and getting their consent as based on 
the national guidelines for animal welfare (no cruelty, providing no 
segregation, even partial, of the animals).
2.2 | Supplement
The commercial supplement Dìnamic™ (Dynamopet srl, Verone, 
Italy), is an association of: Glucosamine sulphate 10%, Krill oil 3%, 
Chondroitine sulphate 1.25%, Ribes nigrum, Krill flour 1%, Lentinus 
edodes, Equisetum arvense, and products obtained from the trans-
formation of herbs (Curcuma longa, Boswellia serrata, Harpagophytum 
procumbens). It aims to improve both acute and chronic arthritis in 
dogs and to increase performance in athlete dogs.
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2.3 | Animals and study design
Twenty cross breed dogs affected by OA (12 males and 8 females; 
mean age 9.2 ± 5.1 years old) were enrolled with the owners’ con-
sent. The study was performed on household dogs to avoid any pos-
sible interference dependent on the usual environmental changes. 
All the dogs were fed for 4 months (including 1 month of adapta-
tion) on a commercial diet (crude protein 211 g kg−1, acid hydrolysed 
ether extract 90 g kg−1, crude fiber 39 g kg−1, 3110 kcal kg−1 as a 
feeding basis) administered using the ratio of 130 kcal ME per kg0.75 
of ideal body weight. All the dogs were enrolled with a clinical diag-
nosis of OA also based on X- rays revealing the beginnings of cracks 
in the cartilage and the growth of bone spurs. The dogs showed, at 
least, intermittent mild lameness and pain in the arthritic joint level. 
No dogs showing comorbidities were included in the trial.
After enrollment, the dogs were randomly equally divided into 
two groups (control group and experimental group), homogeneous by 
sex (6 males and 4 females each). The animals received no pharmaco-
logical treatment for at least 2 months before and all through the trial.
The study was performed in double blind. Dìnamic™ (Dynamopet 
srl, Verone, Italy) was orally administered to the dogs of the exper-
imental group using the ratio of 0.5 ml kg−1 of live weight for 90 
consecutive days, once a day approximately at 9:00 p.m. and placebo 
using the ratio of 0.5 ml kg−1 of live weight was administered to the 
dogs of the control group in order to minimize any false results.
2.4 | Clinical evaluation
The health status of all the dogs was assessed through blood analy-
ses and a clinical examination. These practices were carried out by 
the same vet, before starting the treatment (0) and for each 30- day 
period up to 90 days (30, 60 and 90). Physical examinations, includ-
ing lameness evaluations (overall lameness, pain on manipulation and 
palpation, joint swelling and range of motion), were done at all the 
aformentioned time points as proposed by Pollmeier, Toulemonde, 
Fleishman, and Hanson (2006). The scores for lameness, pain on ma-
nipulation and palpation, range of motion and joint swelling were 
assigned to the most severely affected limb, as determined at the 
initial evaluation. Overall pain during limb manipulation was evalu-
ated by the animals’ vocalization or other psychomotor changes or 
pain expressions during the extension and flexion of all four limbs 
for few min. For each variable, results were graded on a scale of 
0–3: 0 (none), 1 (slight), 2 (moderate) 3 (severe) and, an overall score 
was calculated while placing emphasis on the Pollmeier et al. (2006) 
lameness evaluation:
2.5 | Blood sampling and analyses
Blood samples were collected monthly from the fasting dogs of 
both groups (at 0, 30, 60 and 90 days) from the jugular vein into 
tubes with and without K3- EDTA, and immediately transported to 
the laboratory. Serum was obtained by centrifugation at 1200g for 
15	min,	divided	into	aliquots	and	frozen	at	−80°C.
A complete cell blood count was performed for each whole 
blood sample within 30 min of the collection by a Lasercyte™ hae-
matology analyser (IDEXX Laboratories Inc., Westbrook, Main, USA) 
that provides complete blood counts: white blood cells (WBC), red 
blood cells (RBC), hemoblobin (HGB), hematrocrit (HCT), mean cor-
puscular volume (MCV), mean corpuscular hemoglobin concentra-
tion (MCHC), platelet (PLT), mean platelet volume (MPV), blood cell 
distribution width (RDW), lymphocytes (LYM), monocytes (MON) 
and granulocytes (GRA).
Blood chemistry analyses on serum aliquots were performed 
by an automatic biochemical analyser (AMS Autolab, Diamond 
Diagnostics, USA) using reagents from Spinreact (Girona, Spain) 
to determine: total proteins (TP), albumin (ALB), creatinine (CREA), 
glucose (GLU), aspartate amino transferase (AST), alanineamino-
transferase (ALT), gamma- glutamyltransferase (GGT), bilirubin (BIL), 
lactic dehydrogenase (LDH), alkaline phosphatase (ALP), creatine 
phosphokinase (CPK), cholesterol (CHOL) and triglycerides (TRI).
Reactive oxygen metabolites (the d- ROMs test evaluates the 
free alcohoxyl and hydroperoxyl radicals derived from hydroper-
oxides present in the sample), oxy- adsorbent (the OXY test eval-
uates the total antioxidant barrier understood as the whole of the 
chemically active capacity) and biological antioxidant potential (the 
BAP test evaluates so as to allowthe chemically active antioxidant 
capacity of the plasma barrier to be measured) were also performed 
on serum aliquots using reagents from Diacron International s.r.l. 
(Grosseto, Italy) validated for canine species (Pasquini et al., 2008).
Canine Interleukins 6 (IL- 6) and 10 (IL- 10) and Canine Tumour 
Necrosis alpha (TNF- α) were detected in serum using Elisa kits 
(Genorise, Philadelphia, USA).
2.6 | Statistical analysis
The blood count, blood biochemistry and lameness evaluation data 
were compared by one- way ANOVA (JMP software, SAS Institute, 
NC, USA) according to the following model:
where: y is the dependent variable, μ is the mean, G is the group effect 
(i = Control, Experimental), T is the time effect (j = 0, 30, 60, 90), G × T 
is the first level of interaction and ε is the error effect.
When significant differences were found in the ANOVA, means 
were compared using Tukey's test.
3  | RESULTS
3.1 | Clinical evaluation
All the clinical signs (lameness, pain on manipulation and palpation, 
range of motion and joint swelling) significantly (p < 0.01) improved 
along the trial in the experimental group, which showed significant 
lower joint score than the control group (mean value 3.80 vs. 7.40). 
(2× lameness)+ (pain onmanipulation/palpation)+ (range of motion)
+ (joint swelling)
yijk=휇+Gi+Tj+G×Tij+1ijk.
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Regarding the time effect, the improvement on the overall experi-
mental group score resulted significantly (p < 0.01) lower at the two 
last samplings (mean value 7.70 vs. 2.30 at 60 days and 8.40 vs. 1.30 
at 90 days for the experimental group and the control group, respec-
tively). The interaction between groups resulted as being highly sig-
nificant (p < 0.0001) (Table 1).
3.2 | Haematology and blood chemistry
All the parameters fall within the normal range for adult dogs and no 
signs of adverse effects were observed after the clinical examina-
tion, showing that supplementation was well tolerated. Despite that, 
some significant differences were detected.
Concerning haematology (Table 2), MCV resulted as being sig-
nificantly (p < 0.01) higher in the experimental group compared to 
the control one. MCHC resulted as being significantly (p < 0.05) 
lower during the final sampling (time 90) but no differences were 
observed between the groups.
Concerning blood chemistry (Table 3), the ALP resulted as being 
significantly (p < 0.01) lower in the experimental group compared 
to the control one (113.10 vs. 153.72 U L−1, respectively). CHOL 
significantly decreases (p < 0.01) in the experimental group (189.45 
vs. 207.70 mg dl−1, for E and C groups, respectively) as well as tri-
glycerides (71.47 vs. 96.94 mg dl−1 for E and C groups, respectively).
Concerning the time effect the ALP resulted as being signifi-
cantly (p < 0.01) lower at the end of the experimental period (156.05, 
148.45, 129.70 and 99.45 for 0, 30, 60 and 90 days, respectively). 
The cholesterol resulted as being lower at the final sampling (214.60, 
206.60, 198.30 and 174.80, at 0, 30 60, 90 days, p < 0.01, respec-
tively). The TRI significantly (p < 0.01) decreases from the 60- days 
period until the end of the experimental period (107.10, 84.95, 75.47 
and 96.30 for 0, 30 60, 90 days, respectively).
The interaction between the groups and the time effect resulted 
as being significantly only for the ALP parameter (p < 0.012).
Regarding the oxidative status (Table 4) the d- ROMs signifi-
cantly decreased (p < 0.01) in the experimental group as compared 
TABLE  1 Clinical evaluation of control and experimental groups 
at days 0, 30, 60, 90 in OA dogs
Group effect C E
7.40A 3.80B
Time effect C E
0 6.60AB 6.40AB
30 6.90AB 5.00BC
60 7.70B 2.30CD
90 8.40A 1.30D
G × T <0.0001
RMSE 2.022
Note: Within a column, means without a common letter differ (capital 
letters: p < 0.01 A–D).
Abbreviations: C, Control group; E, Experimental group; RMSE, Root- 
mean- square error. T
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to the control one (55.06 vs. 65.51 U CARR, respectively). 
Similarly, an improvement in the biological antioxidant potential, 
as confirmed by the significant (p < 0.05) increase in the BAP lev-
els, was detected.
No significant differences were recorded for the OXY parameter.
The IL- 6 significantly (p < 0.01) decreased in the E group (206.52 
vs. 178.82 pg ml−1 for the control and experimental group, respec-
tively). On the contrary, the IL- 10 significantly (p < 0.01) increased 
(114.09 vs. 132.38 pg ml−1, respectively). No differences were ob-
served for the TNF-α.
Regarding the time effect d- ROMs significantly (p < 0.01) de-
creased from 30 days up to 90 days. On the contrary, the BAP sig-
nificantly (p < 0.05) improved at the end of the trial. The IL- 6 resulted 
as being significantly (p < 0.01) lower at both 60 and 90 days. The 
IL- 10 resulted higher (p < 0.01) at 90 days.
The interaction between the groups and the time was significant 
(p < 0.01) only for IL- 6.
4  | DISCUSSION
Osteoarthritis is one of the most common causes of lameness in 
dogs. It is caused by a deterioration of the joint cartilage followed 
by pain, inflammation and loss of range of motion of the joint. 
Pharmacological treatment of OA is usually limited to NSAIDs, but 
their use is associated with potential side effects, which can be quite 
adverse (Aghazadeh- Habashi & Jamali, 2011). Therefore, nutritional 
supplements improving the state of patients affected by osteoar-
thritis when they are tolerated well can be of great usefulness for the 
management of OA dogs.
4.1 | Clinical examination
The improvement of the overall score in the experimental group 
was principally ascribable to the reduction of the pain of manipula-
tion (the incidence of subjects with a severe/moderate degree of 
pain decrease from 50 to 0% from the first to the third observation). 
Also, the other clinical parameters of the Pollmeier scale showed a 
significant (p < 0.05) improvement during the trial. These results are 
probably due to the association of different active compounds in 
the formulation of the nutritional supplement. Indeed, the possible 
synergic activity among the various compounds should be assessed 
by specific studies. The anti- inflammatory activity of the Devil's 
claw may be critical in the symptomatic treatment of osteoarthritis 
(Brien et al., 2006) but, also, glucosamine and chondroitin are nutri-
tional supplements which have recently gained widespread use as 
per os treatment options for OA. There is evidence supporting that 
both these compounds reach and retain a certain concentration in 
plasma and in joint fluid and cartilage (Innes, Clayton, & Lascelles, 
2010; Persiani et al., 2007; Vasiliadis & Tsikopoulos, 2017). 
Moreover, also Boswellia serrata, mainly because of its boswellic 
acids, is already known as a mediator in various inflammatory dis-
eases. As reported by Kimmatkar et al. (2003), the administration of T
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Boswellia serrata extracts showed significant reduction in swelling 
and pain and an improvement in the motor skills in patients affected 
by osteoarthritis.
4.2 | Haematology and blood chemistry
Clinical biochemistry as well as haematology showed that the sup-
plementation was well tolerated. The absence of adverse effects is 
often a critical point in the management of chronic diseases. The 
differences in MCV values between those groups associated with a 
normal HCT have no relevant clinical sign. It is well- known that the 
MCV decreases in chronic diseases (Thrall, Weiser, & Jain, 2004), 
even if all the values were comprised in the physiologic range for 
dogs.
In general, triglycerides in serum reflects inflammatory condi-
tions, since they provide additional nutrients that help the metabolic 
requirements of the cells implicated in tissue repair processes (Popa, 
Netea, van Riel, van der Meer, & Stalenhoef, 2007). The decrease 
of the TRI registered in the E group and during the trial suggests 
a reduction in the inflammatory state in the dogs during the ex-
perimental period. Nowadays OA is not considered as only a joint 
disorder associated with mechanical stress and aging but also a ‘met-
abolic syndrome’ in which several risk factors work together con-
tributing to disease initiation and/or development. High cholesterol 
levels have been reported as being one such metabolic risk factor. 
Farnaghi, Crawford, Xiao, and Prasadam (2017) reported that syno-
vial fluid contains a low concentration of cholesterol compared to 
plasma levels whereas the synovial fluid of patients with osteoarthri-
tis has a higher amount of cholesterol and cholesterocrystals than 
the synovial fluid of healthy individuals.
Abdurhman (2003) also reported an association between serum 
cholesterol and OA. Osteoarthritis can cause a reduced physical ac-
tivity and thereby increase of triglycerides and cholesterol. On the 
other hand, an increase in cholesterol can be a predisposing factor 
to osteoarthritis.
The observed reduction in the TRI in the E group and from 
60 days up to the end of the experimental period suggests an im-
provement of bone status and lipid metabolism and is probably due 
to the presence of Krill oil in the formula of the nutritional supple-
ment (Berge et al., 2015). Interestingly enough, despite some of the 
compounds of the formula, this (using the ratio of 832.5 mg EPA and 
DHA per day), is reported to increase cholesterol levels (Berge et al., 
2015), whereas a decrease in CHOL was detected in this trial for 
the experimental group as compared to the control one. Indeed, this 
may be due to the activity of the Boswellia serrata that possesses 
ipo- cholesterolemic activity in humans (Ahangarpour, Heidari, Mard, 
Hashemitabar, & Khodadadie, 2014). This suggests that a studied as-
sociation of different compounds might lead to beneficial effects. In 
this case, two opposite effects resulted in an overall improvement in 
the CHOL in the dogs.
4.3 | Oxidative and inflammation status
Equisetum arvense and Lentinus edodes are probably responsible for 
the improvement of BAP associated with the decrease in d- ROMs in 
the experimental group as compared to C. Experimental outcomes 
reported by Li et al. (2016) showed that Equisetum spp. is consid-
ered an antioxidant ingredient due to its ability to reduce free radi-
cal chain reactions. Moreover, Lentinus edodes, due to its phenolic 
compounds, possess antioxidant capacities, both in vitro (Mishra 
et al., 2013; Naknaen, Itthisoponkul, & Charoenthaikij, 2015) and in 
vivo (Reis, Martins, Barros, & Ferreira, 2012). Interestingly enough, 
OXY results were not statistically significant and such results should 
merit further studies. Both the BAP and OXY allow us to measure 
the chemically active antioxidant capacity (scavengers) but OXY ana-
lyzes the plasmatic structural components such as mucopolysaccha-
rides, amino acids and proteins (shock absorbers) whereas the BAP 
includes antioxidants both of an exogenous nature (ascorbic acid 
and tocopherols) and of an endogenous nature (uric acid, bilirubin 
and albumin) (Lombardi et al., 2017; Morittu et al., 2018). Moreover, 
d- ROMs BAP OXY TNF- α IL- 6 IL- 10
Group effect U CARR μmoli/L mmoli/L pg/ml pg/ml pg/ml
C 65.51A 4232.80b 193.47 134.62 206.52A 114.09B
E 55.06B 4506.70a 196.50 121.18 178.82B 132.38A
Time effect
0 74.65A 4171.15b 188.35 123.73 211.20A 106.88B
30 64.68B 4133.10b 191.50 139.40 235.55A 124.65AB
60 53.53C 4480.00ab 203.70 133.25 157.25B 119.41AB
90 48.30C 4694.75a 196.40 115.23 166.68B 141.99A
G × T
p 0.195 0.139 0.516 0.962 0.001 0.199
RMSE 10.95 451.86 28.46 27.93 41.73 30.11
Note: Within a column, means without a common letter differ (capital letters: p < 0.01; lower case 
letters: p < 0.05). 
Abbreviations: C, Control group; E, Experimental group; RMSE, Root- mean- square error.
TABLE  4 The Oxidative and 
inflammation status of the control and 
experimental groups at days 0, 30, 60, 90 
in OA dogs
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Vassalle et al. (2012) reported that the relationship between the 
global index and the oxidative markers is essentially driven by the 
dROMs test. The relative importance of pro- oxidant and antioxidant 
counterparts on the estimation of the overall oxidative stress status 
can vary in each clinical or experimental setting and depends on the 
evaluated biomarker.
The significant decrease in the IL- 6 and the increase in the IL- 10 
observed in the experimental group as compared to the control one 
and during the trial also confirm the beneficial effects of the nutritional 
supplement. The cytokines are the most universal regulatory system in 
inflammation and host defence against bacterial infection (Aggarwal, 
2007; Popa et al., 2007). They can participate in immunopathologic 
process formation and function as diagnostic markers in some diseases.
Harpagophytum procumbens has been used for centuries to treat in-
flammatory diseases and recently, in Europe, it has been recommended 
for the management of pain and inflammation in OA (Haseeb, Ansari, 
& Haqqi, 2017). Clinical trials report the good tolerability and anti- 
inflammatory effects of Harpagophytum procumbens. This plant exerts 
its anti- inflammatory effects by suppressing the expression of many cy-
tokines (Hostanska, Melzer, Rostock, Suter, & Saller, 2014; Inaba et al., 
2010), in particular, an inhibition of IL- 1β, IL- 6, and TNF- α in mice has 
been reported. In addition, as reported by many authors (Moon et al., 
2006; Wang et al., 2009) curcumin also affects other molecular events 
implicated in the inflammation and the consequent promotion of tumor 
such as inflammatory cytokines (TNFα, interleukins IL- 1, IL- 6 and IL- 8).
Studies in vitro reported that Ribes nigrum is rich in α- linolenic acid 
and possesses anti- inflammatory activities, inhibiting the IL- 6 and 
TNF- α expression, but it also has antioxidant capacities (Wang et al., 
2009). Barre (2001) showed the in vivo anti- inflammatory properties of 
blackcurrant oil, resulting in health effects after human consumption.
Moreover, Krill oil is rich in fatty acids implicated in the regula-
tion of lipid metabolism, adipocyte differentiation and in inflamma-
tory responses. Fish oil had been shown to alter pro- inflammatory 
cytokine production (Zhu, Shi, Qian, Cai, & Li, 2008).
5  | CONCLUSION
The results of this study support the evidence for the benefits of the 
nutritional supplement on animal welfare, improving joints and reduc-
ing pains in dogs with advanced osteoarthritis. The beneficial effects 
suggest that the different components included in the supplement 
may ameliorate the inflammatory state and oxidative stress in terms 
of cellular health by acting with different action mechanisms. Further 
studies are needed to assess the possible synergy among the differ-
ent compounds in determining its overall effectiveness. Moreover, 
the administration which lasted up to 3 months of the studied supple-
ment was well tolerated by the dogs who showed no adverse effects.
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